caa a22 4500 445315784 CHVBK 20180317142646.0 cr unu---uuuuu 170323e20110801xx s 000 0 eng 10.1007/s10552-011-9782-z doi (NATIONALLICENCE)springer-10.1007/s10552-011-9782-z Menopausal hormone therapy and risk of ovarian cancer in the European prospective investigation into cancer and nutrition [Elektronische Daten] [Konstantinos Tsilidis, Naomi Allen, Timothy Key, Laure Dossus, Rudolf Kaaks, Kjersti Bakken, Eiliv Lund, Agnès Fournier, Christina Dahm, Kim Overvad, Louise Hansen, Anne Tjønneland, Sabina Rinaldi, Isabelle Romieu, Marie-Christine Boutron-Ruault, Francoise Clavel-Chapelon, Annekatrin Lukanova, Heiner Boeing, Madlen Schütze, Vassiliki Benetou, Domenico Palli, Franco Berrino, Rocco Galasso, Rosario Tumino, Carlotta Sacerdote, H. Bueno-de-Mesquita, Fränzel van Duijnhoven, Marieke Braem, N. Onland-Moret, Inger Gram, Laudina Rodríguez, Eric Duell, María-José Sánchez, José Huerta, Eva Ardanaz, Pilar Amiano, Kay-Tee Khaw, Nick Wareham, Elio Riboli] The association between menopausal hormone therapy (HT) and risk of ovarian cancer was assessed among 126,920 post-menopausal women recruited into the European Prospective Investigation into Cancer and Nutrition. After an average of 9-year follow-up, 424 incident ovarian cancers were diagnosed. Cox models adjusted for body mass index, smoking status, unilateral ovariectomy, simple hysterectomy, age at menarche, number of full-term pregnancies, and duration of oral contraceptives were used. Compared with baseline never use, current use of any HT was positively associated with risk (HR [hazard ratio], 1.29; 95% CI [confidence interval], 1.01-1.65), while former use was not (HR, 0.96; 95% CI, 0.70-1.30). Current estrogen-only HT was associated with a 63% higher risk (HR, 1.63; 95% CI, 1.08-2.47), while current estrogen plus progestin was associated with a smaller and non-significant higher risk (HR, 1.20; 95% CI, 0.89-1.62). Use of tibolone was associated with a twofold greater risk (HR, 2.19; 95% CI, 1.06-4.50), but was based on small numbers. In conclusion, women who currently use HT have a moderate increased risk of ovarian cancer, and which may be stronger for estrogen-only than estrogen plus progestin preparations. Springer Science+Business Media B.V., 2011 Hormone replacement therapy nationallicence Ovarian cancer nationallicence Cohort study nationallicence Tsilidis Konstantinos Cancer Epidemiology Unit, University of Oxford, Richard Doll Building, Roosevelt Drive, OX3 7LF, Oxford, UK aut Allen Naomi Cancer Epidemiology Unit, University of Oxford, Richard Doll Building, Roosevelt Drive, OX3 7LF, Oxford, UK aut Key Timothy Cancer Epidemiology Unit, University of Oxford, Richard Doll Building, Roosevelt Drive, OX3 7LF, Oxford, UK aut Dossus Laure Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany aut Kaaks Rudolf Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany aut Bakken Kjersti Department of Community Medicine, University of Tromsø, Tromsø, Norway aut Lund Eiliv Department of Community Medicine, University of Tromsø, Tromsø, Norway aut Fournier Agnès Inserm, Centre for Research in Epidemiology and Population Health, U1018, Institut Gustave Roussy, 94805, Villejuif, France aut Dahm Christina Department of Epidemiology, School of Public Health, Aarhus University, Aarhus, Denmark aut Overvad Kim Department of Epidemiology, School of Public Health, Aarhus University, Aarhus, Denmark aut Hansen Louise Institute of Cancer Epidemiology, Danish Cancer Society, Copenhagen, Denmark aut Tjønneland Anne Institute of Cancer Epidemiology, Danish Cancer Society, Copenhagen, Denmark aut Rinaldi Sabina International Agency for Research on Cancer, Lyon, France aut Romieu Isabelle International Agency for Research on Cancer, Lyon, France aut Boutron-Ruault Marie-Christine Inserm, Centre for Research in Epidemiology and Population Health, U1018, Institut Gustave Roussy, 94805, Villejuif, France aut Clavel-Chapelon Francoise Inserm, Centre for Research in Epidemiology and Population Health, U1018, Institut Gustave Roussy, 94805, Villejuif, France aut Lukanova Annekatrin Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany aut Boeing Heiner Department of Epidemiology, German Institute of Human Nutrition, Potsdam, Germany aut Schütze Madlen Department of Epidemiology, German Institute of Human Nutrition, Potsdam, Germany aut Benetou Vassiliki WHO Collaborating Center for Food and Nutrition Policies, Department of Hygiene, Epidemiology and Medical Statistics, University of Athens Medical School, Athens, Greece aut Palli Domenico Molecular and Nutritional Epidemiology Unit, Cancer Research and Prevention Institute (ISPO), Florence, Italy aut Berrino Franco Department of Preventive and Predictive Medicine, National Cancer Institute, Milan, Italy aut Galasso Rocco Istituto di Ricovero e Cura a Carattere Scientifico-Centro di Riferimento Oncologico di Basilicata, Unit of Clinical Epidemiolgy, Biostatistics and Cancer Registry, Rionero in Vulture, Italy aut Tumino Rosario Department of Oncology, Azienda Ospedaliera "Civile—M.P.Arezzo”, Cancer Registry and Histopathology Unit, Ragusa, Italy aut Sacerdote Carlotta Unit of Cancer Epidemiology, University of Turin, Turin, Italy aut Bueno-de-Mesquita H. National Institute for Public Health and the Environment, Bilthoven, The Netherlands aut van Duijnhoven Fränzel National Institute for Public Health and the Environment, Bilthoven, The Netherlands aut Braem Marieke Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands aut Onland-Moret N. Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands aut Gram Inger Department of Community Medicine, University of Tromsø, Tromsø, Norway aut Rodríguez Laudina Public Health and Participation Directorate, Health and Health Care Services Council, Asturias, Spain aut Duell Eric Unit of Nutrition, Environment and Cancer, Cancer Epidemiology Research Program, Catalan Institute of Oncology (ICO-IDIBELL), Barcelona, Spain aut Sánchez María-José Andalusian School of Public Health and CIBER de Epidemiología y Salud Pública, Granada, Spain aut Huerta José Department of Epidemiology, Murcia Regional Health Authority and CIBER de Epidemiología y Salud Pública, Murcia, Spain aut Ardanaz Eva Public Health Institute of Navarra and CIBER de Epidemiología y Salud Pública, Pamplona, Spain aut Amiano Pilar Health Division of Gipuzkoa, Basque Government and IIS BioDonostia and CIBER de Epidemiología y Salud Pública, San Sebastian, Spain aut Khaw Kay-Tee Clinical Gerontology Unit, University of Cambridge, Cambridge, UK aut Wareham Nick Medical Research Council Epidemiology Unit, University of Cambridge, Cambridge, UK aut Riboli Elio Department of Epidemiology and Biostatistics, School of Public Health, Imperial College, London, UK aut Cancer Causes & Control Springer Netherlands 22/8(2011-08-01), 1075-1084 0957-5243 22:8<1075 2011 22 10552 https://doi.org/10.1007/s10552-011-9782-z text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s10552-011-9782-z text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Tsilidis Konstantinos Cancer Epidemiology Unit, University of Oxford, Richard Doll Building, Roosevelt Drive, OX3 7LF, Oxford, UK aut NATIONALLICENCE 700 1- Allen Naomi Cancer Epidemiology Unit, University of Oxford, Richard Doll Building, Roosevelt Drive, OX3 7LF, Oxford, UK aut NATIONALLICENCE 700 1- Key Timothy Cancer Epidemiology Unit, University of Oxford, Richard Doll Building, Roosevelt Drive, OX3 7LF, Oxford, UK aut NATIONALLICENCE 700 1- Dossus Laure Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany aut NATIONALLICENCE 700 1- Kaaks Rudolf Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany aut NATIONALLICENCE 700 1- Bakken Kjersti Department of Community Medicine, University of Tromsø, Tromsø, Norway aut NATIONALLICENCE 700 1- Lund Eiliv Department of Community Medicine, University of Tromsø, Tromsø, Norway aut NATIONALLICENCE 700 1- Fournier Agnès Inserm, Centre for Research in Epidemiology and Population Health, U1018, Institut Gustave Roussy, 94805, Villejuif, France aut NATIONALLICENCE 700 1- Dahm Christina Department of Epidemiology, School of Public Health, Aarhus University, Aarhus, Denmark aut NATIONALLICENCE 700 1- Overvad Kim Department of Epidemiology, School of Public Health, Aarhus University, Aarhus, Denmark aut NATIONALLICENCE 700 1- Hansen Louise Institute of Cancer Epidemiology, Danish Cancer Society, Copenhagen, Denmark aut NATIONALLICENCE 700 1- Tjønneland Anne Institute of Cancer Epidemiology, Danish Cancer Society, Copenhagen, Denmark aut NATIONALLICENCE 700 1- Rinaldi Sabina International Agency for Research on Cancer, Lyon, France aut NATIONALLICENCE 700 1- Romieu Isabelle International Agency for Research on Cancer, Lyon, France aut NATIONALLICENCE 700 1- Boutron-Ruault Marie-Christine Inserm, Centre for Research in Epidemiology and Population Health, U1018, Institut Gustave Roussy, 94805, Villejuif, France aut NATIONALLICENCE 700 1- Clavel-Chapelon Francoise Inserm, Centre for Research in Epidemiology and Population Health, U1018, Institut Gustave Roussy, 94805, Villejuif, France aut NATIONALLICENCE 700 1- Lukanova Annekatrin Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany aut NATIONALLICENCE 700 1- Boeing Heiner Department of Epidemiology, German Institute of Human Nutrition, Potsdam, Germany aut NATIONALLICENCE 700 1- Schütze Madlen Department of Epidemiology, German Institute of Human Nutrition, Potsdam, Germany aut NATIONALLICENCE 700 1- Benetou Vassiliki WHO Collaborating Center for Food and Nutrition Policies, Department of Hygiene, Epidemiology and Medical Statistics, University of Athens Medical School, Athens, Greece aut NATIONALLICENCE 700 1- Palli Domenico Molecular and Nutritional Epidemiology Unit, Cancer Research and Prevention Institute (ISPO), Florence, Italy aut NATIONALLICENCE 700 1- Berrino Franco Department of Preventive and Predictive Medicine, National Cancer Institute, Milan, Italy aut NATIONALLICENCE 700 1- Galasso Rocco Istituto di Ricovero e Cura a Carattere Scientifico-Centro di Riferimento Oncologico di Basilicata, Unit of Clinical Epidemiolgy, Biostatistics and Cancer Registry, Rionero in Vulture, Italy aut NATIONALLICENCE 700 1- Tumino Rosario Department of Oncology, Azienda Ospedaliera "Civile—M.P.Arezzo”, Cancer Registry and Histopathology Unit, Ragusa, Italy aut NATIONALLICENCE 700 1- Sacerdote Carlotta Unit of Cancer Epidemiology, University of Turin, Turin, Italy aut NATIONALLICENCE 700 1- Bueno-de-Mesquita H. National Institute for Public Health and the Environment, Bilthoven, The Netherlands aut NATIONALLICENCE 700 1- van Duijnhoven Fränzel National Institute for Public Health and the Environment, Bilthoven, The Netherlands aut NATIONALLICENCE 700 1- Braem Marieke Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands aut NATIONALLICENCE 700 1- Onland-Moret N. Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands aut NATIONALLICENCE 700 1- Gram Inger Department of Community Medicine, University of Tromsø, Tromsø, Norway aut NATIONALLICENCE 700 1- Rodríguez Laudina Public Health and Participation Directorate, Health and Health Care Services Council, Asturias, Spain aut NATIONALLICENCE 700 1- Duell Eric Unit of Nutrition, Environment and Cancer, Cancer Epidemiology Research Program, Catalan Institute of Oncology (ICO-IDIBELL), Barcelona, Spain aut NATIONALLICENCE 700 1- Sánchez María-José Andalusian School of Public Health and CIBER de Epidemiología y Salud Pública, Granada, Spain aut NATIONALLICENCE 700 1- Huerta José Department of Epidemiology, Murcia Regional Health Authority and CIBER de Epidemiología y Salud Pública, Murcia, Spain aut NATIONALLICENCE 700 1- Ardanaz Eva Public Health Institute of Navarra and CIBER de Epidemiología y Salud Pública, Pamplona, Spain aut NATIONALLICENCE 700 1- Amiano Pilar Health Division of Gipuzkoa, Basque Government and IIS BioDonostia and CIBER de Epidemiología y Salud Pública, San Sebastian, Spain aut NATIONALLICENCE 700 1- Khaw Kay-Tee Clinical Gerontology Unit, University of Cambridge, Cambridge, UK aut NATIONALLICENCE 700 1- Wareham Nick Medical Research Council Epidemiology Unit, University of Cambridge, Cambridge, UK aut NATIONALLICENCE 700 1- Riboli Elio Department of Epidemiology and Biostatistics, School of Public Health, Imperial College, London, UK aut NATIONALLICENCE 773 0- Cancer Causes & Control Springer Netherlands 22/8(2011-08-01), 1075-1084 0957-5243 22:8<1075 2011 22 10552 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer